Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Federal Trade Commission
Accenture
McKinsey
Dow
Cipla
Julphar
Cantor Fitzgerald
Harvard Business School

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,307,100

« Back to Dashboard

Summary for Patent: 4,307,100
Title: Nor bis-indole compounds usable as medicaments
Abstract:Compounds with antitumoral activity corresponding to the formula (I): ##STR1## wherein R'.sub.1 is a hydrogen atom or an alkoxy, acyl, formyl or haloacyl radical; R'.sub.2 is a hydrogen atom or an alkyl radical; R'.sub.3 and R".sub.3 are a hydrogen atom, hydroxyl radical or an alkanoyloxy radical, and together are a carbonyl group, and R'.sub.3 and R'.sub.5 together are an epoxy bridge or a double bond; R'.sub.4 is a hydrogen atom or an alkyloxycarbonyl, hydroxymethyl, alkanoyloxymethyl or acetamido radical; R'.sub.5 and R".sub.5 are a hydrogen atom or a hydroxyl, alkanoyloxyl, ethyl or 2-hydroxyethyl radical; R'.sub.6 is a hydrogen atom or an ethyl, 2-hydroxyethyl or acetyl radical; R.sub.1 is a hydrogen atom or an alkyl, formyl or acyl radical; R.sub.2 is a hydrogen atom or alkoxy radical; R.sub.3 is a hydrogen atom or a hydroxyl or alkanoyloxyl radical, and together with R.sub.4 is an epoxy bridge or a double bond; R.sub.4 is a hydrogen atom or a hydroxyl, alkanoyloxyl radical, and together with R.sub.5 is an epoxy bridge; R.sub.6 is an alkyloxycarbonyl, hydrazido, acetamido, hydroxymethyl or alkanoyloxymethyl radical; and R.sub.5 and R.sub.7 are a hydrogen atom or a hydroxyl and alkanoyloxyl radical; acid addition and quaternary ammonium salts thereof and 12-chloro derivatives thereof.
Inventor(s): Langlois; Nicole (Bures S. Yvette, FR), Langlois; Yves (Bures S. Yvette, FR), Andriamialisoa; Ratremaniaina Z. (Les Ulis, FR), Potieo; Pierre (Bois d'Arcy, FR), Mangeney; Pierre (Paris, FR)
Assignee: Agence Nationale de Valorisation de la Recherche (ANVAR) (Paris, FR)
Application Number:06/067,439
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 4,307,100

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 4,307,100

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France78 24568Aug 24, 1978
France78 24569Aug 24, 1978
France79 02981Feb 06, 1979

International Family Members for US Patent 4,307,100

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 0010458 ➤ Sign Up SPC/GB96/037 United Kingdom ➤ Sign Up
France 2434171 ➤ Sign Up
France 2434172 ➤ Sign Up
Germany 2966049 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
US Army
Julphar
Queensland Health
UBS
McKinsey
Cipla
Baxter
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.